全文获取类型
收费全文 | 44545篇 |
免费 | 4802篇 |
国内免费 | 340篇 |
专业分类
耳鼻咽喉 | 1122篇 |
儿科学 | 1115篇 |
妇产科学 | 702篇 |
基础医学 | 4298篇 |
口腔科学 | 766篇 |
临床医学 | 5369篇 |
内科学 | 9414篇 |
皮肤病学 | 941篇 |
神经病学 | 4132篇 |
特种医学 | 1873篇 |
外科学 | 8710篇 |
综合类 | 433篇 |
现状与发展 | 2篇 |
一般理论 | 40篇 |
预防医学 | 3844篇 |
眼科学 | 865篇 |
药学 | 2644篇 |
中国医学 | 31篇 |
肿瘤学 | 3386篇 |
出版年
2024年 | 116篇 |
2023年 | 743篇 |
2022年 | 610篇 |
2021年 | 1365篇 |
2020年 | 1342篇 |
2019年 | 1177篇 |
2018年 | 1801篇 |
2017年 | 1416篇 |
2016年 | 1572篇 |
2015年 | 1655篇 |
2014年 | 2392篇 |
2013年 | 2959篇 |
2012年 | 3122篇 |
2011年 | 3131篇 |
2010年 | 2114篇 |
2009年 | 2229篇 |
2008年 | 2703篇 |
2007年 | 2525篇 |
2006年 | 2434篇 |
2005年 | 2339篇 |
2004年 | 2161篇 |
2003年 | 1925篇 |
2002年 | 1774篇 |
2001年 | 355篇 |
2000年 | 269篇 |
1999年 | 385篇 |
1998年 | 560篇 |
1997年 | 506篇 |
1996年 | 551篇 |
1995年 | 448篇 |
1994年 | 342篇 |
1993年 | 263篇 |
1992年 | 212篇 |
1991年 | 207篇 |
1990年 | 135篇 |
1989年 | 189篇 |
1988年 | 158篇 |
1987年 | 119篇 |
1986年 | 119篇 |
1985年 | 125篇 |
1984年 | 140篇 |
1983年 | 126篇 |
1982年 | 143篇 |
1981年 | 94篇 |
1980年 | 86篇 |
1979年 | 50篇 |
1978年 | 66篇 |
1977年 | 62篇 |
1976年 | 43篇 |
1975年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.